Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs in Canada? A Review of Submissions to the Canadian Agency for Drugs and Technologies in Health Common Drug Review

Orphan drugs have high acquisition costs and when standard health technology assessment (HTA) approaches are used to assess their cost-effectiveness, they often appear not cost-effective. The Canadian Patented Medicine Review Board (PMPRB), through new regulations, will apply HTA assessment results...

Descripción completa

Detalles Bibliográficos
Autores principales: Balijepalli, Chakrapani, Gullapalli, Lakshmi, Druyts, Eric, Yan, Kevin, Desai, Kamal, Barakat, Stephane, Locklin, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455764/
https://www.ncbi.nlm.nih.gov/pubmed/32922050
http://dx.doi.org/10.2147/CEOR.S264589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455764/
https://www.ncbi.nlm.nih.gov/pubmed/32922050
http://dx.doi.org/10.2147/CEOR.S264589

Ejemplares similares